SCHEMBL4334161

SCHEMBL4334161

Nc1ccc(Oc2ccnc(C(=O)O)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ KDM6B O15054 1/20 0.47
▸ TET3 O43151 1/20 0.47
▸ KDM4A O75164 1/20 0.47
▸ BBOX1 O75936 1/20 0.47
▸ KDM5A P29375 1/20 0.47
▸ KDM5C P41229 1/20 0.47
▸ ASPH Q12797 1/20 0.47
▸ KDM4D Q6B0I6 1/20 0.47
▸ TET2 Q6N021 1/20 0.47
▸ ALKBH5 Q6P6C2 1/20 0.47
▸ KDM7A Q6ZMT4 1/20 0.47
▸ KDM8 Q8N371 1/20 0.47
▸ TET1 Q8NFU7 1/20 0.47
▸ EGLN2 Q96KS0 1/20 0.47
▸ FTO Q9C0B1 1/20 0.47
▸ EGLN1 Q9GZT9 1/20 0.47
▸ KDM4C Q9H3R0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2889234 0.90 GCK (0.52) MEN1KMT2AKDRMAOABRAF
SCHEMBL177841 0.87 PARP10 (0.54) ALDH1A1MAPTSMN1; SMN2PARP10MEN1
SCHEMBL6386070 0.87 KDR (0.47) ALDH1A1KDM4EKDRBRAFRAF1
SCHEMBL6383415 0.86 KDR (0.47) ALDH1A1MAPTSMN1; SMN2PARP10MEN1
SCHEMBL28790568 0.86 NR4A1 (0.53) ALDH1A1KDM4EMAPTKDM6BTET3
SCHEMBL4365227 0.85 KDM4E (0.49) ALDH1A1KDM4EMAPTKDM6BTET3
SCHEMBL22737610 0.85 GCK (0.54) ALDH1A1KDM4EMAPTKDM6BTET3
SCHEMBL3409437 0.84 MAOB (0.54) ALDH1A1KDM4EMAPTKDM6BTET3
SCHEMBL903580 0.84 P2RX3 (0.53) ALDH1A1KDM4EMAPTKDM6BTET3
SCHEMBL2427202 0.84 P2RX3 (0.52) ALDH1A1KDM4EMAPTKDM6BTET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111298127-A Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same 黄泳华 2020-06-19 — — CN claimed
US-20240139194-A1 PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS VIBLIOME THERAPEUTICS, LLC 2024-05-02 — — US disclosed
CN-112624967-A Sorafenib mercapto derivative and application thereof 复旦大学 2021-04-09 — — CN disclosed
CN-111298127-A Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same 黄泳华 2020-06-19 — — CN disclosed
EP-2739143-B1 PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS FLYNN GARY A (US) 2018-07-11 — — EP disclosed
US-9833455-B2 Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors SPACEFILL ENTERPRISES LLC (US) 2017-12-05 — — US disclosed
US-20160303128-A1 PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS VIBLIOME THERAPEUTICS, LLC 2016-10-20 — — US disclosed
CN-105801475-A Method for preparing sorafenib tosylate 华润双鹤利民药业(济南)有限公司 2016-07-27 — — CN disclosed
US-9221805-B2 Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors Spacefill Enterprises LLP (US) 2015-12-29 — — US disclosed
US-20140228367-A1 PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS VIBLIOME THERAPEUTICS, LLC 2014-08-14 — — US disclosed
WO-2008115263-A2 RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2008-09-25 — — WO disclosed
US-20080234332-A1 RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. 2008-09-25 — — US disclosed
US-20080221132-A1 Multi-Functional Small Molecules as Anti-Proliferative Agents CURIS, INC. 2008-09-11 — — US disclosed
US-20080221132-A1 Multi-Functional Small Molecules as Anti-Proliferative Agents CURIS, INC. 2008-09-11 — — US disclosed
US-20080221132-A1 Multi-Functional Small Molecules as Anti-Proliferative Agents CURIS, INC. 2008-09-11 — — US disclosed
WO-2008033747-A9 MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS CURIS INC (MA) 2008-07-24 — — WO disclosed
WO-2008033747-A2 MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS CURIS, INC. (US) 2008-03-20 — — WO disclosed
US-20060189665-A1 Oxamide derivatives useful as raf-kinase inhibitors MERCK PATENT GMBH (DE) 2006-08-24 — — US disclosed
EP-1606260-A1 OXAMIDE DERIVATIVES USEFUL AS RAF-KINASE INHIBITORS MERCK PATENT GmbH (DE) 2005-12-21 — — EP disclosed
WO-2004085399-A1 OXAMIDE DERIVATIVES USEFUL AS RAF-KINASE INHIBITORS MERCK PATENT GMBH (DE) 2004-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139194-A1 PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS ABL1, ERBB2, MAP3K2 ALDH1A1 3761/4885KDM4E 941/4885MAPT 2839/4885
US-20080221132-A1 Multi-Functional Small Molecules as Anti-Proliferative Agents HDAC1, HDAC6, HDAC5 ALDH1A1 2328/4885KDM4E 916/4885MAPT 3758/4885
US-20160303128-A1 PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS ABL1, ERBB2, MAP3K2 ALDH1A1 3761/4885KDM4E 941/4885MAPT 2839/4885
US-20140228367-A1 PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS ABL1, ERBB2, MAP3K2 ALDH1A1 3761/4885KDM4E 941/4885MAPT 2839/4885
US-20080234332-A1 RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY BRAF, RAF1, BAZ2B ALDH1A1 2000/4885KDM4E 1190/4885MAPT 3181/4885
US-20060189665-A1 Oxamide derivatives useful as raf-kinase inhibitors BRAF, RAF1, ARAF ALDH1A1 921/4885KDM4E 849/4885MAPT 3212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback